argenx SE
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
15 mei 2015 - 07:17
Statutaire naam
argenx SE
Titel
arGEN-X Reports First Quarter 2015 Financial Results and Provides Business Update
Bericht
Breda, the Netherlands / Ghent, Belgium, 15 May 2015- arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today provided development program updates and announced financial results for the first quarter ended March 31, 2015.
Datum laatste update: 24 maart 2025